Lyra Therapeutics to Present at Upcoming Virtual Investor Conferences

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D., Lyra`s President and Chief Executive Officer, will present in a virtual format at three upcoming investor conferences:  

The Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum – corporate presentation on November 18, 2021 at 9:00 a.m. ET

The Evercore ISI 4th Annual HealthCONx Virtual Conference – fireside chat on December 1, 2021 at 3:55 p.m. ET

Webcasts of the virtual presentations will be available in the Investor Relations section of the Company`s website at https://investors.lyratherapeutics.com at the times and dates specified above. Webcast replays will be available for 30 days following each event.

About Lyra Therapeutics

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, local delivery of medications to diseased tissues not accessible with conventional therapeutic approaches. Lyra`s XTreo™ platform is comprised of a biocompatible mesh scaffold, an engineered elastomeric matrix and a versatile polymer-drug complex. The company`s current pipeline of therapeutics target tissues deep in the ear, nose and throat passages and are designed to deliver continuous drug therapy for up to six months following a single non-invasive, in-office administration. Lyra`s lead product candidate, LYR-210, is entering Phase 3 clinical development for the treatment of chronic rhinosinusitis (CRS) as an alternative to primary sinus surgery. Lyra`s second product candidate, LYR-220, is entering Phase 2 development and is designed to be an alternative to revision CRS sinus surgery and post-surgical medical management. For more information, please visit www.lyratherapeutics.com and follow us on LinkedIn and Twitter.